Complications of a Stepwise Approach for Transvenous Lead Extraction

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04306575
Collaborator
(none)
100
1
17
5.9

Study Details

Study Description

Brief Summary

It is an observational study of predictors of complications and difficulty of trans-venous lead extraction procedure. This procedure is done for patient who had a previous cardiac pacemaker or defibrillator implantation which had a dysfunction or infection so needed to be extracted.

Condition or Disease Intervention/Treatment Phase
  • Other: Trans-venous lead extraction

Detailed Description

The number of cardiac implantable electronic device (CIED) implantations has increased over recent years (1) with approximately 1.2-1.4 million CIEDs are being implanted annually worldwide.(2) Consequently this has been associated with increasing rates of infection and lead malfunctions, affecting approximately 1-2% of all CIED cases.(3)

Recently, it is estimated that between 10 000 and 15 000 leads are extracted worldwide each year.(4) Over the past few decades, transvenous lead extraction (TLE) has evolved as the preferred method for leads removal being less invasive compared to surgical removal by open heart surgery which is now reserved for cases with high risk procedures or a very large vegetation.

Most frequent indications for TLE are infection (accounting for 52.8%) and lead dysfunction (accounting for 38.1%) of all cases of TLE. (5)

There have been different approaches (superior and inferior approaches) and techniques for TLE. Current techniques employ mechanical and/or laser equipment with variable success rates. The locking stylet has been the principal tool in these techniques, while the telescoping (powered or non-powered) mechanical or laser sheaths serve as the most important ancillary tools.

Despite being a safe procedure with minor complications ranging from 0.06 to 6.2%, but serious complications may still arise in 0.2-1.8 % of cases in even the most experienced hands with mortality rates in several large registries amounting 0.2 - 1.2 %.(6) Although many studies have tried to identify risk factors for complications including patient/lead profile and centre/operator experience, major studies still have conflicting results.

Recently, the hybrid approach, with mini-thoracotomy or thoracoscopy, has been introduced and supposed to be associated with increased safety in challenging TLE procedures. (7, 8)

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Other
Official Title:
Challenges and Complications of a Stepwise Approach for Transvenous Lead Extraction, Single High-Volume Center Study
Anticipated Study Start Date :
Mar 1, 2020
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Aug 1, 2021

Outcome Measures

Primary Outcome Measures

  1. Procedural related major complications [one year]

    Complications includes pericardial effusion/tamponade, arrhythmia, hypotension, pulmonary embolism and death

Secondary Outcome Measures

  1. Clinical and radiological success [3 months]

    clinical success means that the procedure completed with no procedural complications, Radiological success means complete extraction of the whole lead or remaining of less than 3 cm

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All consecutive patients referred for lead extraction with class I and IIa indications according to 2017 HRS expert consensus statement on CIED lead management and extraction.
Exclusion Criteria:
  • Patients primarily requiring surgical extraction

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brescia university hospital Brescia Italy

Sponsors and Collaborators

  • Assiut University

Investigators

  • Principal Investigator: Antonio Curnis, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mohamed Aboelhassan Abdelrady Mohamed, Assistant lecturer, Assiut University
ClinicalTrials.gov Identifier:
NCT04306575
Other Study ID Numbers:
  • 01020031284
First Posted:
Mar 13, 2020
Last Update Posted:
Mar 13, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Mar 13, 2020